The Company’s proprietary mass spec analysis platform enables the rapid discovery and evaluation of diagnostic signatures. In contrast to other techniques the analysis is truly high-throughput (over the past 2 years we have analyzed over 3,500 patient samples resulting in over 35,000 mass spectra), it does not require complicated laboratory procedures, nor expensive analysis kits (as genomic analysis requires). The Company has shown that they can rapidly discover, evaluate and validate mass spec based diagnostic signatures in the whole range of cancer biomarker research and welcomes collaborators. See Collaborations.

The Company has numerous projects underway and its areas of focus are in oncology and degenerative diseases. Within oncology, the Company continues its research into early diagnostic tools for verifying lung cancer in high-risk populations, diagnosis of cancer in males with elevated PSA, alternatives to existing techniques for identifying HER2 positive breast cancer patients, stratifying aggressive cancers from more benign forms, stratifying patients for reactions to targeted therapies in lung and other cancers, and similar efforts.

The majority of the Company’s work has been on serum or tissue samples. However, we have experience analyzing other types of biological specimens (urine, CSF, EPF, FNA, LCM, Tissue, etc.).